- Home
- LAMR vs RPRX Comparison
LAMR vs RPRX Comparison
Compare LAMR & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LAMR
- RPRX
- Stock Information
- Founded
- LAMR 1902
- RPRX 1996
- Country
- LAMR United States
- RPRX United States
- Employees
- LAMR N/A
- RPRX N/A
- Industry
- LAMR Real Estate Investment Trusts
- RPRX Biotechnology: Pharmaceutical Preparations
- Sector
- LAMR Real Estate
- RPRX Health Care
- Exchange
- LAMR Nasdaq
- RPRX Nasdaq
- Market Cap
- LAMR 12.1B
- RPRX 13.9B
- IPO Year
- LAMR 1996
- RPRX 2020
- Fundamental
- Price
- LAMR $123.54
- RPRX $36.51
- Analyst Decision
- LAMR Buy
- RPRX Strong Buy
- Analyst Count
- LAMR 6
- RPRX 3
- Target Price
- LAMR $131.83
- RPRX $48.33
- AVG Volume (30 Days)
- LAMR 562.2K
- RPRX 3.8M
- Earning Date
- LAMR 08-08-2025
- RPRX 08-07-2025
- Dividend Yield
- LAMR 5.01%
- RPRX 2.41%
- EPS Growth
- LAMR N/A
- RPRX 37.60
- EPS
- LAMR 4.11
- RPRX 2.45
- Revenue
- LAMR $2,220,416,000.00
- RPRX $2,263,845,000.00
- Revenue This Year
- LAMR $4.78
- RPRX $29.35
- Revenue Next Year
- LAMR $3.54
- RPRX $7.58
- P/E Ratio
- LAMR $30.08
- RPRX $14.88
- Revenue Growth
- LAMR 3.72
- RPRX 1.13
- 52 Week Low
- LAMR $99.84
- RPRX $24.05
- 52 Week High
- LAMR $139.88
- RPRX $36.69
- Technical
- Relative Strength Index (RSI)
- LAMR 55.13
- RPRX 63.23
- Support Level
- LAMR $121.89
- RPRX $35.51
- Resistance Level
- LAMR $129.78
- RPRX $36.56
- Average True Range (ATR)
- LAMR 2.96
- RPRX 0.62
- MACD
- LAMR 0.12
- RPRX -0.03
- Stochastic Oscillator
- LAMR 45.97
- RPRX 89.29
About LAMR Lamar Advertising Company
Lamar Advertising Co is an outdoor advertising companies in the United States and operates as a Real Estate Investment Trust. It rent space for advertising on billboards, buses, shelters, benches, logo plates and in airport terminals and also offer customers a fully integrated service with all aspects of their display requirements from ad copy production to placement and maintenance. It has two operating segments: billboard and Others. Key revenue is generated from Billboard segment.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.